Roche’s CINtec PLUS Cytology Receives the US FDA’s Approval as the First Biomarker-Based Triage Test to Improve the Prevention of Cervical Cancer

 Roche’s CINtec PLUS Cytology Receives the US FDA’s Approval as the First Biomarker-Based Triage Test to Improve the Prevention of Cervical Cancer

Roche’s CINtec PLUS Cytology Receives the US FDA’s Approval as the First Biomarker-Based Triage Test to Improve the Prevention of Cervical Cancer

Shots:

  • The US FDA has approved Roche’s CINtec PLUS Cytology as the first biomarker-based triage test for women with HPV positive results, screened by using the Cobas 4800 HPV test. The approval is based on IMPACT study validating CINtec PLUS Cytology as a triage test in different screening scenarios in 35,000+ women in the US
  • Roche’s Cobas 4800 HPV test in combination with CINtec PLUS Cytology and CINtec Histology aids clinicians to improve the detection of cervical pre-cancer. The CINtec PLUS Cytology test is anticipated to be available in the US in H2’20
  • CINtec PLUS Cytology is the only test that utilizes dual-biomarker technology to detect p16 and Ki-67 simultaneously, thus providing an indication towards the presence of transforming HPV infections

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: CNBC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post